SPRO earnings

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases w

CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare di

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero, along with its development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 Existing cash and earned and non-contingent development milestone payments from GSK provide anticipated runway to fund the Company's current operating expenses and capital expenditures into 2028 CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company foc

CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update. To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this link and request a return call with passcode 0605709. The audio webcast can be

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review and reprioritization of the Company's pipeline in Q1 2025 Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.   To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this li

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments fo

Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024New SPR720 in-vitro resistance data to be presented at IDWeek 2024 conference in OctoberCompany announces departure of Chief Medical Officer Kamal Hamed, MD, MPH, MBA; Appoints Board member and Chair of Development Committee John C. Pottage, Jr., M.D., as Special Advisor to oversee medical function; search ongoing for a new CMOCash balance of $63.5 million as of June 30, 2024; reiterate expected cash runway into late 2025Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Aug. 05, 2024 (GLO

CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline. To access the call, please dial 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and refer to conference ID 13747505, or click on this link and request a return call. The audio w

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference call, and anticipates resuming quarterly earnings calls at the time it announces second quarter 2024 results. About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is

On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Initiated enrollment in PIVOT-PO, a pivotal Phase 3 clinical trial of oral Tebipenem HBr in cUTI Submitted IND for SPR206 and received FDA clearance to proceed with Phase 2 clinical trialReiterate expected cash runway into late 2025Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR)

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13744458, or click on this Link and request a

Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2023, and provided a business update. "Having made substantial progress across our late-stage pr

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13741831, or click on this link and req

SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Sath Shukla Became President and CEO, Effective August 1 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, announced today financial results for the second quarter ended June 30, 2023, and provided a business u

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, August 10, 2023 at 4:30 p.m. ET to report its second quarter 2023 financial results and provide an update on its business and pipeline. To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10022241, or click on this link and re

Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD) on track for top line data readout in 1H 2024 Update on status of Special Protocol Assessment agreement for tebipenem HBr program expected mid-year 2023; initiation of Phase 3 trial in complicated urinary tract infection (cUTI) expected in 2H 2023 Conference call and webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an update on its business and pipeline. To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10021779, or click on this link and req

Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024 Exclusive license agreement with GSK for tebipenem HBr provided Spero with $66 million upfront, a $9 million direct equity investment, and eligibility for future milestone payments and tiered royalties Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MD

CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it has changed the date of its previously announced 2022 fourth quarter and full year earnings release and conference call from today, Monday, March 13, 2023 to Thursday, March 30, 2023. Spero is still evaluating the accounting treatment associated with the GSK transaction in 2022 and needs additional time to complete its audit and file its Annual Report on

CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, March 13, 2023 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13736217, or click on this lin

Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million direct equity investment in Spero shares of common stock, with potential for future milestone payments and tiered royalties Initiation of a placebo-controlled Phase 2 trial designed to provide clinical proof-of-concept for SPR720 in nontuberculous mycobacterial pulmonary disease with top line results expected in 1H 2024 Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) today announced financial results for the third quarter ended September 30,

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to report its third quarter 2022 financial results and provide an update on its business and pipeline. To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10020538. The audio webcast can be acce

Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Resistant Pathogen Trial of SPR206 Expected in 3Q 2023 Continued Engagement with FDA is Expected to Provide Key Insights into the Path Forward for Tebipenem HBr Conference Call and Live Webcast at 4:30 p.m. ET Today CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) today announced financial results for the second quarter ended June 30, 2022 and provided a business update. "We believe Spero is well positioned to create value with a clear strategic focus, stro

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an update on its business and pipeline. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13731565. The audio webcast can be accessed under "Events and Presentations" in the Investor and Media section of the Company's website at www.sperotherapeutics.com. The archived webcast will also be available on Spero's website for 30 days following the call.

New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem's Optimal Path to Value Creation Initiation of a Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial-Pulmonary Disease Expected in 2H 2022 SPR206's Phase 1 Data Support Further Development in Complicated Urinary Tract Infection, Hospital-acquired and Ventilator-associated Bacterial Pneumonia, and Bloodstream Infections Conference Call and Live Webcast at 4:30 p.m. ET Today CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) today announced financial results for the first quarter ended March 31, 2022 and provided a business update. "While our re

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30 p.m. ET to report its first quarter 2022 financial results and provide an update on its business and pipeline. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13729221. The audio webcast can be accessed under "Events and Presentations" in the Investor and Media section of the Company's website at www.sperotherapeutics.com. The archived webcast will also be available on Spero's website for 30 days following the call. About S

Announces Immediate Cessation of Tebipenem HBr Commercialization Initiatives; Company to Shift Focus to Advancement of SPR720 and SPR206 Spero to Explore Strategic Partnerships and Other Opportunities for Tebipenem HBr                      Conference Call and Live Webcast at 8:30 a.m. ET Today CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it will immediately defer current commercialization activities fo

Provides update on ongoing FDA review of Tebipenem HBr NDA Phase 2 trial of SPR720 in nontuberculous mycobacterial-pulmonary disease on track for initiation in 2H 2022 following lifting of FDA clinical hold Topline results from Phase 1 bronchoalveolar lavage trial support further development of SPR206 in the setting of hospital-acquired pneumonia and ventilator-associated pneumonia Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) today announced financial results for the fourth quarter and full-year ended December 31, 2021 and provided a business update. The U.S. Food and Drug Administrat

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022, at 4:30 p.m. ET to report its fourth quarter and full-year 2021 financial results and provide an update on its business and pipeline. To access the call, please dial 1-877-705-6003 (domestic) or 1-201-493-6725 (international) and refer to conference ID 13727002. The audio webcast can be accessed under "Events and Presentations" in the Investor and Media section of the Company's website at www.sperotherapeutics.com. The archived webcast will also be available on Spero's website for 30 days foll

Submitted NDA to U.S. FDA for tebipenem HBr for the treatment of complicated urinary tract infections, including pyelonephritis Entered into a non-dilutive revenue interest financing agreement with HealthCare Royalty Partners® for up to $125 million Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced financial results for the third quarter ended September 30, 2021,

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021, at 4:30 p.m. ET to report its third quarter 2021 financial results and provide an update on its business and pipeline. To access the call please dial 800-263-0877 (domestic) or 646-828-8143 (international) and refer to conference ID 5314099. The audio webcast can be accessed unde

Tebipenem HBr on track for NDA submission in the fourth quarter of 2021 Announced $40 million equity investment from Pfizer Inc. and licensing agreement for SPR206 Initiated Phase 1 bronchoalveolar lavage and renal impairment clinical trials of SPR206 Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in areas of high unmet need, involving multi-drug resistant bacterial infections and rare diseases, today announced financial results for the second quarter ended June 30,

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on August 5, 2021, at 4:30 p.m. ET to report its second quarter 2021 financial results and provide an update on its business and pipeline. To access the call please dial 800-239-9838 (domestic) or 323-794-2551 (international) and refer to conference ID 1395205. The audio webcast can be accessed under "Events